Conference Description:

This fifth annual event will gather a global audience of biosimilar experts and industry-thought leaders to discuss biosimilar manufacturing and commercialization considerations specific to the U.S.
Fresh from the press: On March 7th, 2018, the U.S.-FDA's Commissioner, Scott Gottlieb, MD, announced that Biosimilar medicines are now a top priority for the FDA. Join us this November to learn how to take advantage of the FDA's focus on biosimilars, accelerate your biosimilar pipeline and achieve FDA approval.
Hear from a selection of carefully handpicked keynote addresses and case studies presented to you by top manufacturing and leading distributors of market approved biosimilars, as they offer a unique insight into the areas of manufacturing, commercialization, device design, uptake, switching, interchangeability, and regulations.
This event is CPD accredited.

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 25th September 2018, Copthorne Tara Hotel, Central London, UK
Workshop A: Decoding how Stakeholders may Drive Biosimilar Adoption
Workshop B: Dealing with Life Sciences Patents at the PTAB

WHO SHOULD ATTEND
Medical Directors, Scientific Directors, VP's, Directors, Managers, Team Leaders, Partners, Consultants and Attorneys of:
Biosimilars, Biobetters, Biopharmaceuticals, Biostatistics, Business Alliances, Business Development, Clinical Operations, Commercial, Decision Analytics, Global Intelligence, Global Operations, Managed Markets and Trade Relations, Market assess, Marketing, Patient And Physician Services, R And D Policy, Regulatory Affairs, Scientific Affairs, and anyone else who works within the biosimilars industry!

EARLY BIRD-RATES
- BOOK BY JUNE 29TH AND SAVE US$300
- BOOK BY SEPTEMBER 28TH AND SAVE US$100

TARGETED KEYWORDS
Biosimilar, Biobetters, biologic, generic drug, immunogenicity, innovator, interchangeability, pharmacist, doctors, dosage, legislation, medicine

URLs:
Tickets: https://go.evvnt.com/236852-0?pid=154
Brochure: https://go.evvnt.com/236852-3?pid=154
Tickets: https://go.evvnt.com/236852-4?pid=154

Prices:
Conference And 2 Workshops: USD 2997.0
Conference And 1 Workshop: USD 2498.0
Conference only : USD 1999.0
2 Workshops only : USD 998.0
1 Workshop only: USD 499.0
Promotional Literature Distribution : USD 1198.8

Speakers: Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Christina Yunis, Global Biosimilars Market Development Lead, Pfizer Essential Health, Nigel Rulewski, Vice President Strategic Drug Development, Head Biosimilar Center of Excellence, IQVIA, Houng Kim, Head of Strategy And Operations Division, Celltrion Healthcare, Anita Burrell, Principal, Anita Burrell Consulting, Sarfaraz Niazi, Founder, Karyo Biologics, LLC, Hillel Cohen, Executive Director, Scientific Affairs, Sandoz, Don Stewart, CEO, PlantForm Corporation, Arun Nataraj, Senior Director, Business Development And Corporate Strategy, Amneal Pharmaceuticals, Hiten Gutka, Principal Scientist Formulation Development Biosimilar Development, Oncobiologics, Catherine Soo, Senior Clinical Evaluator, Health Canada, Steinar Madsen, Medical Director, Norwegian Medicines Agency, Magdalena Leszczyniecka, President and CEO, STCBiologics, Tucker Herbert, Manager, ZS Associates, Christina Corridon, Associate Principal, ZS Associates, Ha Kung Wong, Partner, New York, Fitzpatrick, Cella, Harpper And Scinto, John Kirkland, Director, Intellectual Property, Alkermes, Inc.

Time: 8:30 am to 4:30 pm